HC Wainwright Issues Optimistic Outlook for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Investment analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Friday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.67) for the quarter, up from their prior forecast of ($0.72). HC Wainwright has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.86) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.71) EPS, FY2027 earnings at ($2.60) EPS, FY2028 earnings at ($2.52) EPS, FY2029 earnings at ($1.75) EPS and FY2030 earnings at ($0.28) EPS.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Monday, April 20th. Robert W. Baird lifted their price objective on Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Morgan Stanley lifted their price objective on Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a report on Monday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Denali Therapeutics Stock Up 0.3%

NASDAQ DNLI opened at $19.67 on Tuesday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $20.10 and its two-hundred day moving average is $18.90. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -6.83 and a beta of 0.99. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the company earned ($0.78) EPS.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Foresite Capital Management VI LLC bought a new position in Denali Therapeutics in the 3rd quarter worth approximately $14,520,000. AlphaQuest LLC raised its position in Denali Therapeutics by 224.1% in the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after purchasing an additional 51,458 shares during the last quarter. Aberdeen Group plc raised its position in Denali Therapeutics by 23.4% in the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock worth $16,169,000 after purchasing an additional 210,835 shares during the last quarter. Principal Financial Group Inc. raised its position in Denali Therapeutics by 18.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after purchasing an additional 198,207 shares during the last quarter. Finally, Capricorn Fund Managers Ltd bought a new position in Denali Therapeutics in the 4th quarter worth approximately $1,027,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Denali Therapeutics and raised multiple earnings estimates for 2026-2030, signaling improved expectations for the company’s longer-term profitability. Denali Therapeutics (NASDAQ:DNLI) Given “Buy” Rating at BTIG Research
• Positive Sentiment: BTIG Research also reaffirmed its Buy rating and set a $39 price target, reinforcing the bullish analyst sentiment around DNLI. BTIG Research Reiterates Buy Rating
• Neutral Sentiment: HC Wainwright’s updated estimates still point to losses in the near term, but the revisions were generally upward for 2026-2029 earnings, which may be seen as a gradual improvement rather than a fundamental breakthrough.
• Neutral Sentiment: Recent short-interest data showed essentially no meaningful short position reported, so it does not appear to be a major current driver of the stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.